THE HFA INSTITUTE 2019

Financing 102: TBA and MBS -**Comparing TBA and Mortgage Revenue Bond Executions**

National Council of

HOME and **Housing Trust** Fund **JANUARY 13 - 15**













Housing Credit JANUARY 15 – 17




















THE HFA INSTITUTE 2019 Financing 102: TBA and MBS





Comparing Mortgage Revenue Bond (MRB) Execution to TBA/MBS










Comparing Mortgage Revenue Bond (MRB) Execution to TBA/MBS

• The Fed is no longer replacing MBS prepays. The market has changed.







- No simple "apples-to-apples" comparison.
 - On Bonds: HFA is compensated over time with \$ from permitted 1.125% bond-to-mortgage-yield spread.
 - On TBA/MBS: HFA is compensated when MBS is delivered, all \$ upfront.
- Are there exceptions? Can an HFA receive \$ up-front on a bond transaction? Can an HFA receive \$ over time on MBS?
 - On bonds ... difficult to pocket cash.
 - On TBA/MBS...\$ over time maybe, but we are not talking about the exception here.







Financing 102: TBA and MBS

Comparing MRB Execution to TBA/MBS

- A fair comparison? Fully informed use of NPV rate.
- Present value of <u>expected</u> future cash flows on bonds. What \$ today which, if invested at X%, would replicate the future MRB cash flow to the HFA?

or

- Can we future value the investment of TBA/MBS receipts? What is the \$ value in the future of TBA/MBS receipts today, invested at X%?
- Rather than take the known thing (TBA/MBS price) and project into the future (how would I know how you plan to use the \$?) the easiest and the traditional comparison has been to simply to present value bond cash flow.
- What is a reasonable X%? Remember, NPV@ 2.5% is bigger than @ 3.5% because you would need a lot more theoretical \$ today to replicate actual \$ from bonds received in the future.
- If your expected investment rate for TBA/MBS money received today is really a low %, then use it as NPV%! Resulting larger NPV of bond CF tells you that TBA/MBS \$ received today [and reinvested at low %] should be bigger.







- A fair comparison? Comparing MRB projections to known TBA/MBS.
- On Bonds: Underlying loans prepay. They can prepay very slowly or very quickly. A fair comparison shows NPV% across a range of prepayment possibilities.

Prepayment Speed (PSA%)	NPV% or \$ on Bonds	VS.	TBA/MBS % or \$
100%	3.70%		
200%	2.40%	VS.	5555
300%	1.65%		
400%	1.25%		
•	•		
•	•		
•	•		

 Assumptions for cash out: HFA fee? Use surplus to call bonds until 100% redeemed or only use prepays?







- A fair comparison? What about loan term assumptions?
- A fair comparison will use the same assumptions on both sides.
- Does analysis use 50%/50% mix of GNMA/FN-FHs? Do it on both sides. For HFA, do you know you are looking at 50/50? Are you really 100% GNMA?
- Is HFA paid a servicing release premium (SRP) by a master servicer? How are lenders compensated? Carefully examine assumptions to ensure analysis is not accidentally skewed. (e.g. TBAs use 56.5bp svc when MRBs based on 44bp)
- What if HFA contributes \$ to bond deal? Add it to TBA/MBS, or run bond analyses with no contribution (less \$ for mortgages).
- COI/negative arbitrage included in bonds?
- Disclose assumptions!







Comparing MRB Execution to TBA/MBS – One Example

- Bonds \sim same, 12/21/18 1/9/18; 100% fixed-rate, serials, terms, premium PAC structure, no points to mortgagors; \$ shortfalls from reso. to cover any neg. arb. are reimbursed.
- Loans 4.75%/5.00% GN/FN-FH, Average 1% SRP & 2.125% lender comp are the same.
- No points; lender compensation paid by the program.

MR	B Financed Mo	ortgage Loans (12/21/18-1/9/1	.9)			TBA Net Pro	ofit to HFA	
Prepayment	NPV of	HFA Fee and S	urplus @ NPV%	Shown		Date	GNMA	FNMA	Average/Ttl
Speed	2.5%	3.0%	3.5%	4.0%	<u>ADVANTAGE:</u>	12/21/2018	1.331%	0.483%	0.907%
50%	3.4%	3.0%	2.7%	2.5%		12/26/2018	1.253%	0.545%	0.899%
100%	4.5%	4.0%	3.6%	3.2%	- MRB	12/31/2018	1.409%	0.733%	1.071%
200%	2.9%	2.7%	2.4%	2.2%		1/2/2019	1.691%	1.061%	1.376%
300%	2.0%	1.8%	1.7%	1.6%		1/4/2019	1.894%	1.279%	1.587%
400%	1.4%	1.3%	1.3%	1.2%	├ TBA ——	1/7/20 19	1.909%	1.232%	1.571%
500%	1.4%	1.3%	1.2%	1.1%	_	1/9/2019	1.550%	0.951%	1,251%

(at given PSA speed, gross CF projections are identical but NPV, the \$

which if invested at %, by definition will be lower for higher % reinvest)

• Prepay speeds would need to be fairly high for TBA to be better than MRBs.







Comparing MRB Execution to TBA/MBS – One Example

- Custom MBS pools move the dial for TBA but in today's market you need a lot.
- With 1% pay-up (shown below), TBA economics improve relative to MRB but a strong case can still be made for MRBs in low rate environment.



MR	B Financed Mo	ortgage Loans (12/21/18-1/9/1	L9)	
Prepayment	NPV of	HFA Fee and S	urplus @ NPV%	6 Shown	
Speed	2.5%	3.0%	3.5%	4.0%	ADVANTAGE:
50%	3.4%	3.0%	2.7%	2.5%	<u> </u>
100%	4.5%	4.0%	3.6%	3.2%	- MRB
200%	2.9%	2.7%	2.4%	2.2%	_
300%	2.0%	1.8%	1.7%	1.6%]
400%	1.4%	1.3%	1.3%	1.2%	- тва
500%	1.4%	1.3%	1.2%	1.1%	

	TBA Net Pro	fit to HFA	
IF HFA RECE	IVES AVG. C	F 1% PAY	-UP ON TBA
Date	Average/Tt	Add-On	Total for TBA
12/21/2018	0.907%	1.00%	1.907%
12/26/2018	0.899%	1.00%	1.899%
12/31/2018	3 1.071%	1.00%	2.071%
1/2/2019	1.376%	1.00%	2.376%
1/4/2019	1.587%	1.00%	2.587%
1/7/2019	1.571%	1.00%	2.571%
1/9/2019	1.251%	1.00%	2.251%







- MRB loan rates look relatively good. Any downside?
 - Yes rates can go down!
 - Bloomberg consensus forecasts for 2019 Fed Funds completely flipped the last two weeks of December

reu	runus Day C	OT FOIVIC IVIO	ve rutures K	ate
FOMC	Target Rate Pr	ojections (as o	f December 19	9, 2018)
Rate Increase	-25 bps	Current Rate	+25 bps	+50 bps
Target Rate	2.00 - 2.25%	2.25 - 2.50%	2.50-2.75%	2.75 -3.00%
1/30/2019	0.0%	97.9%	2.1%	0.0%
3/20/2019	0.0%	78.1%	21.5%	0.4%
5/1/2019	0.0%	73.2%	25.0%	1.7%
6/19/2019	0.0%	63.8%	31.3%	4.7%
7/31/2019	0.0%	60.7%	32.8%	6.0%
9/18/2019	0.0%	55.5%	35.2%	8.3%
10/30/2019	0.0%	55.2%	34.1%	8.4%
12/1/2019	2.4%	54.4%	30.3%	8.1%

FOM	C Target Rate I	Projections (as	of January 3,	2019)
Rate Increase	-25 bps	Current Rate	+25 bps	+50 bps
Target Rate	2.00 - 2.25%	2.25 - 2.50%	2.50-2.75%	2.75 -3.00%
1/30/2019	6.7%	93.3%	0.0%	0.0%
3/20/2019	15.1%	84.3%	0.0%	0.0%
5/1/2019	19.4%	79.1%	0.0%	0.0%
6/19/2019	24.2%	72.7%	0.0%	0.0%
7/31/2019	27.4%	67.8%	0.0%	0.0%
9/18/2019	30.9%	62.0%	0.0%	0.0%
10/30/2019	34.1%	55.5%	0.0%	0.0%
12/1/2019	37.0%	48.0%	0.0%	0.0%


January 2 - Fed Funds Move Futures Rate







- Downside to bonds? (other than returns dependent on % prepays)
 - Rates continue to go down.
 - Lots of bond issuance in Oct.-Nov. is now ~ 0.25%+ "behind".
 - If you have bond proceeds, would you shift production to TBA in a falling rate environment?









- Enhancing bonds?
 - Bond programs more easily produce DPA. Not always easy to do with TBA.
 - HFAs may opt to take additional risk, using swaps, for example, to lower MRB financing costs. Unlike MRBs it is difficult to lower the cost of TBA financing.
- In the current market, the problem with both TBA and MRB is that neither produces rates that are low enough.
 - National average mortgage APR = 5.15% (FHA; 680-699 FICO).
 - Our 4.75%/5.00% examples have lender compensation paid.
 - Is this competitive in your state?
 - TBA and MRB rates can be (just barely) lowered to 4.50%/4.75% GN/FN-FH.







- Where do we go from here?
 - "Normalized" TBA
 - No sub-prime craziness
 - MRBs back to 2006-2007 levels ...
 - the good retail support, strong institutional interest and no real whole loan market penalty
 - the bad after the GSEs stopped buying MRBs, spreads spiked







• 40+ HFAs have the ability to finance through both MRBs and TBA. HFAs have already won. For now, when choosing between MRBs and TBA, the winner is!



THE HFA INSTITUTE 2019





The information contained herein is solely intended to facilitate discussion of potentially applicable financing applications and is not intended to be a specific buy/sell recommendation, nor is it an official confirmation of terms. Any terms discussed herein are preliminary until confirmed in a definitive written agreement. While we believe that the outlined financial structure or marketing strategy is the best approach under the current market conditions, the market conditions at the time any proposed transaction is structured or sold may be different, which may require a different approach.

The analysis or information presented herein is based upon hypothetical projections and/or past performance that have certain limitations. No representation is made that it is accurate or complete or that any results indicated will be achieved. In no way is past performance indicative of future results. Changes to any prices, levels, or assumptions contained herein may have a material impact on results. Any estimates or assumptions contained herein represent our best judgment as of the date indicated and are subject to change without notice. Examples are merely representative and are not meant to be all-inclusive.

Raymond James shall have no liability, contingent or otherwise, to the recipient hereof or to any third party, or any responsibility whatsoever, for the accuracy, correctness, timeliness, reliability or completeness of the data or formulae provided herein or for the performance of or any other aspect of the materials, structures and strategies presented herein. Raymond James is neither acting as your financial advisor nor Municipal Advisor (as defined in Section 15B of the Exchange Act of 1934, as amended), and expressly disclaims any fiduciary duty to you in connection with the subject matter of this Presentation.

Municipal Securities Rulemaking Board ("MSRB") Rule G-17 requires that we make the following disclosure to you at the earliest stages of our relationship, as underwriter, with respect to an issue of municipal securities: the underwriter's primary role is to purchase securities with a view to distribution in an arm'slength commercial transaction with the issuer and it has financial and other interests that differ from those of the issuer.

Raymond James does not provide accounting, tax or legal advice; however, you should be aware that any proposed transaction could have accounting, tax, legal or other implications that should be discussed with your advisors and/or legal counsel.

Raymond James and affiliates, and officers, directors and employees thereof, including individuals who may be involved in the preparation or presentation of this material, may from time to time have positions in, and buy or sell, the securities, derivatives (including options) or other financial products of entities mentioned herein. In addition, Raymond James or affiliates thereof may have served as an underwriter or placement agent with respect to a public or private offering of securities by one or more of the entities referenced herein. (continued)

THE HFA INSTITUTE 2019





This Presentation is not a binding commitment, obligation, or undertaking of Raymond James. No obligation or liability with respect to any issuance or purchase of any Bonds or other securities described herein shall exist, nor shall any representations be deemed made, nor any reliance on any communications regarding the subject matter hereof be reasonable or justified unless and until (1) all necessary Raymond James, rating agency or other third party approvals, as applicable, shall have been obtained, including, without limitation, any required Raymond James senior management and credit committee approvals, (2) all of the terms and conditions of the documents pertaining to the subject transaction are agreed to by the parties thereto as evidenced by the execution and delivery of all such documents by all such parties, and (3) all conditions hereafter established by Raymond James for closing of the transaction have been satisfied in our sole discretion. Until execution and delivery of all such definitive agreements, all parties shall have the absolute right to amend this Presentation and/or terminate all negotiations for any reason without liability therefor.

The information presented herein may include references to swaps or other derivative products and associated risks is provided for informational purposes only, and is meant to be only a general summary of various derivative product and strategies that may be available. Raymond James ("RJ") is not acting as your agent, advisor or fiduciary. RJ has not assumed a fiduciary responsibility in your favor with respect to the information provided and nothing in any prior relationship between you and RJ creates an advisory, fiduciary or agency relationship between you and RJ in respect of the information provided. Raymond James is not expressing an opinion as to whether you should enter into a swap or other derivative product. This Proposal does not include a complete explanation of swaps or their associated risks, may be based upon limited information and is not meant to constitute a recommendation and cannot be relied upon in making an investment or financing decision. There are many risks associated with the use of swaps and other derivative products and before any decision with respect to the use of swaps or other derivative products can be made, you should receive a complete proposal that details such associated risks, which may be significant. You should identify, in consultation with your own legal, tax, accounting and financial advisors [qualified independent representative, municipal advisors], but without reliance upon RJ or any of its affiliates, the financial and economic risks and merits, as well as the legal, tax and accounting characterizations and consequences, of any such proposed transaction and determine whether such transaction would be in your best interest, including whether you have the capacity to assume such risks.